Drug Target Strategies in Breast Cancer Treatment: Recent Developments

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 14, 10 Issues, 2014


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 22nd of 58 in Chemistry, Medicinal
  • 85th of 202 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.939
5 - Year: 3.37

Drug Target Strategies in Breast Cancer Treatment: Recent Developments

Author(s): Vikas Jaitak

Affiliation: Centre for Chemical and Pharmaceutical Sciences Central University of Punjab, Bathinda, India-151001

Abstract

Breast cancer (BC) is the leading cause of death among women all over the world. Estrogen receptor (ER) based therapy is one of the major approach to treat BC and is associated with various problems such as primary as well as secondary resistance. ER signaling is a complex pathway as many factors are involved, including several type of estrogen receptors (ERs) and their associated co-regulators. Increasing understanding of ER signaling results in new approaches targeting towards BCs. In this context, ER co-regulators have been explored and presently many modulators of ER co-regulators are known in literature. EGFR and mTOR pathways have also significant impact on BC endocrine therapy because of complex crosstalk mechanism which is the main cause of primary and secondary resistance. The other harder form of BC is Triple negative breast cancer (TNBC) that is majorly associated with BRCA mutation. Currently there is no approved targeted therapy available for such form of cancer but PARP inhibitors seem to be suitable candidates. Various advancements are going on in the field of BC targeted therapy and this review focused on the current scenario of ER , EGFR, as well as mTOR signaling target therapy. We have also discussed the current status of PARP inhibitor in BC chemotherapy


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 14
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1871520614666140407114853
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science